AZ's Gout Drug Gets FDA Go-Ahead With Safety Caveats
This article was originally published in Scrip
The US FDA has approved AstraZeneca's Zurampic (lesinurad) to treat treat high levels of uric acid in the blood associated with gout. The approval, for its use in combination with a xanthine oxidase inhibitor (or XOI, such as allopurinol or febuxostat, which reduce uric acid production), is conditional upon AstraZeneca completing a postmarketing study to further evaluate the drug's renal and cardiovascular safety. Zurampic has a boxed warning about the raised risk of acute kidney failure when Zurampic is used without an XOI and with higher than approved doses.
You may also be interested in...
ACR Notebook: Lilly's Baricitinib Differentiates On Pain, Ironwood's Duzallo Progress, Corbus Nears Phase III
The ACR/ARHP Annual Meeting in San Diego offered new details from studies of new and existing therapies across a range of rheumatic diseases, from rheumatoid arthritis to rare diseases. Scrip shares notes here from interviews with Lilly, Ironwood, Corbus and Samumed.
What was AstraZeneca's trash is now Ironwood's treasure, as it pays $100m up front, along with milestones and royalties, to acquire gout drug approved in December, but not yet launched.
From the latest COVID-19 advances to the emergence of a game changer for heart failure, Scrip’s editor in chief Eleanor Malone reviews the big stories of the past three months. Safety issues around JAK inhibitors and AAV vector-based gene therapy were also to the fore, while biopharma financing continued apace.